Copyright Reports & Markets. All rights reserved.

Global GnRH Agonist Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of GnRH Agonist
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global GnRH Agonist Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Prostap
    • 1.3.3 Zoladex
    • 1.3.4 Triptorelin
    • 1.3.5 Histrelin
    • 1.3.6 Nafarelin
    • 1.3.7 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global GnRH Agonist Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 For Human
    • 1.4.3 For Veterinary
  • 1.5 Global GnRH Agonist Market Size & Forecast
    • 1.5.1 Global GnRH Agonist Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global GnRH Agonist Sales Quantity (2018-2029)
    • 1.5.3 Global GnRH Agonist Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 Pfizer
    • 2.1.1 Pfizer Details
    • 2.1.2 Pfizer Major Business
    • 2.1.3 Pfizer GnRH Agonist Product and Services
    • 2.1.4 Pfizer GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Pfizer Recent Developments/Updates
  • 2.2 AbbVie
    • 2.2.1 AbbVie Details
    • 2.2.2 AbbVie Major Business
    • 2.2.3 AbbVie GnRH Agonist Product and Services
    • 2.2.4 AbbVie GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 AbbVie Recent Developments/Updates
  • 2.3 AstraZeneca
    • 2.3.1 AstraZeneca Details
    • 2.3.2 AstraZeneca Major Business
    • 2.3.3 AstraZeneca GnRH Agonist Product and Services
    • 2.3.4 AstraZeneca GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 AstraZeneca Recent Developments/Updates
  • 2.4 Ferring
    • 2.4.1 Ferring Details
    • 2.4.2 Ferring Major Business
    • 2.4.3 Ferring GnRH Agonist Product and Services
    • 2.4.4 Ferring GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Ferring Recent Developments/Updates
  • 2.5 TerSera Therapeutics
    • 2.5.1 TerSera Therapeutics Details
    • 2.5.2 TerSera Therapeutics Major Business
    • 2.5.3 TerSera Therapeutics GnRH Agonist Product and Services
    • 2.5.4 TerSera Therapeutics GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 TerSera Therapeutics Recent Developments/Updates
  • 2.6 Astellas Pharma
    • 2.6.1 Astellas Pharma Details
    • 2.6.2 Astellas Pharma Major Business
    • 2.6.3 Astellas Pharma GnRH Agonist Product and Services
    • 2.6.4 Astellas Pharma GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Astellas Pharma Recent Developments/Updates
  • 2.7 Takeda
    • 2.7.1 Takeda Details
    • 2.7.2 Takeda Major Business
    • 2.7.3 Takeda GnRH Agonist Product and Services
    • 2.7.4 Takeda GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Takeda Recent Developments/Updates
  • 2.8 LIVZON
    • 2.8.1 LIVZON Details
    • 2.8.2 LIVZON Major Business
    • 2.8.3 LIVZON GnRH Agonist Product and Services
    • 2.8.4 LIVZON GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 LIVZON Recent Developments/Updates
  • 2.9 Ipsen
    • 2.9.1 Ipsen Details
    • 2.9.2 Ipsen Major Business
    • 2.9.3 Ipsen GnRH Agonist Product and Services
    • 2.9.4 Ipsen GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Ipsen Recent Developments/Updates
  • 2.10 Sanofi
    • 2.10.1 Sanofi Details
    • 2.10.2 Sanofi Major Business
    • 2.10.3 Sanofi GnRH Agonist Product and Services
    • 2.10.4 Sanofi GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Sanofi Recent Developments/Updates
  • 2.11 Endo
    • 2.11.1 Endo Details
    • 2.11.2 Endo Major Business
    • 2.11.3 Endo GnRH Agonist Product and Services
    • 2.11.4 Endo GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Endo Recent Developments/Updates
  • 2.12 Tocris Bioscience
    • 2.12.1 Tocris Bioscience Details
    • 2.12.2 Tocris Bioscience Major Business
    • 2.12.3 Tocris Bioscience GnRH Agonist Product and Services
    • 2.12.4 Tocris Bioscience GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Tocris Bioscience Recent Developments/Updates
  • 2.13 Sigma-Aldrich
    • 2.13.1 Sigma-Aldrich Details
    • 2.13.2 Sigma-Aldrich Major Business
    • 2.13.3 Sigma-Aldrich GnRH Agonist Product and Services
    • 2.13.4 Sigma-Aldrich GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Sigma-Aldrich Recent Developments/Updates
  • 2.14 MedChem Express
    • 2.14.1 MedChem Express Details
    • 2.14.2 MedChem Express Major Business
    • 2.14.3 MedChem Express GnRH Agonist Product and Services
    • 2.14.4 MedChem Express GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 MedChem Express Recent Developments/Updates
  • 2.15 Arbor Pharmaceuticals
    • 2.15.1 Arbor Pharmaceuticals Details
    • 2.15.2 Arbor Pharmaceuticals Major Business
    • 2.15.3 Arbor Pharmaceuticals GnRH Agonist Product and Services
    • 2.15.4 Arbor Pharmaceuticals GnRH Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 Arbor Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: GnRH Agonist by Manufacturer

  • 3.1 Global GnRH Agonist Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global GnRH Agonist Revenue by Manufacturer (2018-2023)
  • 3.3 Global GnRH Agonist Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of GnRH Agonist by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 GnRH Agonist Manufacturer Market Share in 2022
    • 3.4.2 Top 6 GnRH Agonist Manufacturer Market Share in 2022
  • 3.5 GnRH Agonist Market: Overall Company Footprint Analysis
    • 3.5.1 GnRH Agonist Market: Region Footprint
    • 3.5.2 GnRH Agonist Market: Company Product Type Footprint
    • 3.5.3 GnRH Agonist Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global GnRH Agonist Market Size by Region
    • 4.1.1 Global GnRH Agonist Sales Quantity by Region (2018-2029)
    • 4.1.2 Global GnRH Agonist Consumption Value by Region (2018-2029)
    • 4.1.3 Global GnRH Agonist Average Price by Region (2018-2029)
  • 4.2 North America GnRH Agonist Consumption Value (2018-2029)
  • 4.3 Europe GnRH Agonist Consumption Value (2018-2029)
  • 4.4 Asia-Pacific GnRH Agonist Consumption Value (2018-2029)
  • 4.5 South America GnRH Agonist Consumption Value (2018-2029)
  • 4.6 Middle East and Africa GnRH Agonist Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global GnRH Agonist Sales Quantity by Type (2018-2029)
  • 5.2 Global GnRH Agonist Consumption Value by Type (2018-2029)
  • 5.3 Global GnRH Agonist Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global GnRH Agonist Sales Quantity by Application (2018-2029)
  • 6.2 Global GnRH Agonist Consumption Value by Application (2018-2029)
  • 6.3 Global GnRH Agonist Average Price by Application (2018-2029)

7 North America

  • 7.1 North America GnRH Agonist Sales Quantity by Type (2018-2029)
  • 7.2 North America GnRH Agonist Sales Quantity by Application (2018-2029)
  • 7.3 North America GnRH Agonist Market Size by Country
    • 7.3.1 North America GnRH Agonist Sales Quantity by Country (2018-2029)
    • 7.3.2 North America GnRH Agonist Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe GnRH Agonist Sales Quantity by Type (2018-2029)
  • 8.2 Europe GnRH Agonist Sales Quantity by Application (2018-2029)
  • 8.3 Europe GnRH Agonist Market Size by Country
    • 8.3.1 Europe GnRH Agonist Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe GnRH Agonist Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific GnRH Agonist Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific GnRH Agonist Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific GnRH Agonist Market Size by Region
    • 9.3.1 Asia-Pacific GnRH Agonist Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific GnRH Agonist Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America GnRH Agonist Sales Quantity by Type (2018-2029)
  • 10.2 South America GnRH Agonist Sales Quantity by Application (2018-2029)
  • 10.3 South America GnRH Agonist Market Size by Country
    • 10.3.1 South America GnRH Agonist Sales Quantity by Country (2018-2029)
    • 10.3.2 South America GnRH Agonist Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa GnRH Agonist Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa GnRH Agonist Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa GnRH Agonist Market Size by Country
    • 11.3.1 Middle East & Africa GnRH Agonist Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa GnRH Agonist Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 GnRH Agonist Market Drivers
  • 12.2 GnRH Agonist Market Restraints
  • 12.3 GnRH Agonist Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry
  • 12.5 Influence of COVID-19 and Russia-Ukraine War
    • 12.5.1 Influence of COVID-19
    • 12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

  • 13.1 Raw Material of GnRH Agonist and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of GnRH Agonist
  • 13.3 GnRH Agonist Production Process
  • 13.4 GnRH Agonist Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 GnRH Agonist Typical Distributors
  • 14.3 GnRH Agonist Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global GnRH Agonist market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
    GnRH, also known as gonadotropin-releasing hormone, is a peptide hormone secreted by the hypothalamus, which further stimulates the pituitary gland to release and synthesize gonadotropins, including follicle-stimulating hormone and luteinizing hormone. Controls the function of the ovary and the function of the testis. GnRH agonists are generally referred to as gonadotropin-releasing hormone agonists. Gonadorelin-releasing hormone agonists generally include triptorelin acetate injection, gonadorelin for injection, leuprolide acetate microspheres for injection and other drugs.
    The Global Info Research report includes an overview of the development of the GnRH Agonist industry chain, the market status of For Human (Prostap, Zoladex), For Veterinary (Prostap, Zoladex), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of GnRH Agonist.
    Regionally, the report analyzes the GnRH Agonist markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global GnRH Agonist market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the GnRH Agonist market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the GnRH Agonist industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (Kilogram), revenue generated, and market share of different by Type (e.g., Prostap, Zoladex).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the GnRH Agonist market.
    Regional Analysis: The report involves examining the GnRH Agonist market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the GnRH Agonist market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to GnRH Agonist:
    Company Analysis: Report covers individual GnRH Agonist manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards GnRH Agonist This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (For Human, For Veterinary).
    Technology Analysis: Report covers specific technologies relevant to GnRH Agonist. It assesses the current state, advancements, and potential future developments in GnRH Agonist areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the GnRH Agonist market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    GnRH Agonist market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
    Market segment by Type
    Prostap
    Zoladex
    Triptorelin
    Histrelin
    Nafarelin
    Others
    Market segment by Application
    For Human
    For Veterinary
    Major players covered
    Pfizer
    AbbVie
    AstraZeneca
    Ferring
    TerSera Therapeutics
    Astellas Pharma
    Takeda
    LIVZON
    Ipsen
    Sanofi
    Endo
    Tocris Bioscience
    Sigma-Aldrich
    MedChem Express
    Arbor Pharmaceuticals
    Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe GnRH Agonist product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of GnRH Agonist, with price, sales, revenue and global market share of GnRH Agonist from 2018 to 2023.
    Chapter 3, the GnRH Agonist competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the GnRH Agonist breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
    Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and GnRH Agonist market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
    Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
    Chapter 13, the key raw materials and key suppliers, and industry chain of GnRH Agonist.
    Chapter 14 and 15, to describe GnRH Agonist sales channel, distributors, customers, research findings and conclusion.

    Buy now